Home Drug IndexClinical Monograph

Loperamide Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antidiarrhoeal

Subclass

Peripheral opioid receptor agonist

Speciality

Gastroenterology

Schedule (India)

Schedule H

Routes

Oral

Formulations

2 mg tablets
2 mg capsules
1 mg/5 mL oral suspension

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Acute Non-specific Diarrhoea (Adults)

Parameter	Recommendation
Starting dose	4 mg (2 tablets/capsules) initially
Titration	2 mg after each unformed stool
Usual maintenance dose	4–8 mg/day
Maximum dose	16 mg/day

Clinical Notes:

Do not exceed 48 hours of treatment without clinical reassessment
Discontinue if no improvement within 48 hours
Ensure adequate oral rehydration alongside antimotility therapy

2. Chronic Diarrhoea (e.g., IBS-D, Short Bowel Syndrome)

Parameter	Recommendation
Starting dose	4 mg/day in divided doses
Titration	Increase by 2 mg/day based on response
Usual maintenance dose	4–8 mg/day in 2–4 divided doses
Maximum dose	16 mg/day

Clinical Notes:

If no improvement after 10 days, reassess diagnosis and management
Long-term use may help reduce stool frequency but does not address bloating or abdominal discomfort
Consider specialist referral for persistent symptoms

3. Diarrhoea Associated with Ileostomy

Parameter	Recommendation
Starting dose	4 mg/day in divided doses
Titration	Adjust based on stoma output
Usual maintenance dose	4–8 mg/day
Maximum dose	16 mg/day

Clinical Notes:

Aim to reduce excessive stoma output and fluid losses
Gastroenterology or surgical specialist supervision recommended
Monitor hydration and electrolyte status regularly

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Label Status	Evidence Basis
Traveller's Diarrhoea	Starting: 2–4 mg stat; then 2 mg after each loose stool; Max: 16 mg/day	Short-term only (≤48 hours)	OFF-LABEL	Indian specialist practice; limited RCT data

Cautions for Off-label Use:

Avoid in presence of fever, bloody stools, or suspected invasive bacterial infection (Shigella, Salmonella, EHEC)
Risk of ileus increases with invasive pathogens
Use only as adjunct to rehydration and antimicrobials where indicated

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indication: Acute Diarrhoea

Age Group	Weight Range	Dose	Maximum Daily Dose
<2 years	Any	NOT RECOMMENDED	—
2–5 years	13–20 kg	1 mg (5 mL) twice daily	6 mg/day
6–8 years	20–30 kg	2 mg/day in 2 divided doses	8 mg/day
9–12 years	>30 kg	2 mg three times daily	8 mg/day

Duration: Not more than 2–3 days without clinical reassessment

Safety Monitoring:

Discontinue immediately if abdominal distension or reduced bowel sounds develop
Monitor hydration status and serum electrolytes
Exercise extra caution in malnourished or significantly dehydrated children
Oral rehydration remains the cornerstone of diarrhoea management in children

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Label Status	Evidence Basis
Chronic diarrhoea in short bowel syndrome	Titrated individually	Long-term under supervision	OFF-LABEL; Specialist only	Limited paediatric case series; Indian GI specialist practice

Age Restriction:

Not recommended in children below 2 years due to risk of paralytic ileus and fatal respiratory depression

Renal Adjustments

No dose adjustment required.

Hepatic adjustment

Contraindications

Age below 2 years
Acute dysentery (bloody or mucoid stools)
Febrile diarrhoea or suspected invasive bacterial enteritis
Pseudomembranous colitis (Clostridioides difficile infection)
Known hypersensitivity to loperamide or any excipients
Severe hepatic impairment

Cautions

HIV-positive patients with diarrhoea (risk of toxic megacolon if underlying infectious colitis)
Elderly patients (increased risk of constipation and bowel distension)
Dehydrated or malnourished patients
Prolonged or repeated use may delay diagnosis of underlying pathology
Extended use can cause rebound constipation

Pregnancy

Parameter	Recommendation
Risk category	Generally considered safe based on available data; limited human studies
Preferred alternative	Oral rehydration therapy is first-line
When may be used	Short-term use under obstetric guidance if rehydration alone is insufficient
Monitoring	Watch for signs of constipation and reduced gut motility

Lactation

Parameter	Recommendation
Compatibility	Compatible with breastfeeding
Drug levels in milk	Very low
Preferred status	Preferred over diphenoxylate-atropine combinations
Infant monitoring	Observe for constipation, reduced feeding, or unusual drowsiness

Elderly

Starting dose: Begin at 2 mg; titrate cautiously
Titration: Slower than in younger adults
Extra risks: Increased susceptibility to constipation, paralytic ileus, and abdominal distension
Monitoring: Regularly assess bowel sounds and abdominal examination

Major drug interactions

Interacting Drug/Class	Mechanism/Effect	Recommendation
P-glycoprotein inhibitors (quinidine, ritonavir, verapamil)	Increased CNS penetration of loperamide	Avoid combination; CNS depression risk
Strong CYP3A4/CYP2C8 inhibitors (ketoconazole, itraconazole, gemfibrozil)	Elevated loperamide plasma levels	Avoid or use with extreme caution
QT-prolonging drugs (at high loperamide doses)	Additive QT prolongation	Risk of torsades de pointes; avoid supratherapeutic dosing

Moderate drug interactions

Interacting Drug/Class	Mechanism/Effect	Recommendation
CNS depressants (benzodiazepines, opioids)	Additive sedation (mainly at abuse-level doses)	Monitor for excessive drowsiness
Anticholinergic drugs	Increased risk of paralytic ileus	Unidentified
Oral cholera vaccine	Reduced vaccine immunogenicity	Avoid concurrent administration

Common Adverse effects

Constipation
Abdominal cramps
Nausea
Flatulence
Dizziness
Dry mouth

Serious Adverse effects

Toxic megacolon (especially if used in infectious colitis)
Paralytic ileus
CNS depression (particularly in hepatic impairment or overdose/abuse)
QT prolongation and ventricular arrhythmias (reported with supratherapeutic doses or abuse)
Anaphylaxis (rare)

Monitoring requirements

Timing	Parameters
Baseline	Hydration status, serum electrolytes, clinical assessment for invasive infection
After initiation	Bowel sounds, abdominal distension, stool frequency
Chronic use	Bowel pattern, CNS symptoms (if hepatic dysfunction suspected), electrolyte balance

Brands in India

Lopedim® (Cipla)
Imodium® (Janssen)
Lopamide®
Lomedon®

Note: Lomotil® contains diphenoxylate-atropine — it is a different drug.

Price range (INR)

Formulation	Approximate Price
Tablets (2 mg)	₹1–₹3 per tablet
Capsules (2 mg)	₹1–₹3 per capsule
Oral suspension (30 mL)	₹20–₹35 per bottle

NLEM Status: Not included in NLEM 2022; price variation exists across brands.

Clinical pearls

Always exclude invasive bacterial diarrhoea (fever, blood/mucus in stool) before prescribing — loperamide is contraindicated in such cases
In acute diarrhoea, treatment beyond 48 hours without reassessment is inappropriate
For IBS-D, low-dose loperamide may reduce stool frequency but has limited effect on bloating or pain
Avoid in patients with hepatic impairment — reduced first-pass metabolism increases CNS toxicity risk
Contraindicated below age 2 years due to risk of serious respiratory and GI complications
Be vigilant for loperamide abuse (high doses for opioid effects) — associated with fatal cardiac arrhythmias

Version

RxIndia v1.0 — 28 May 2025

Reference

- CDSCO product listings
- Indian Pharmacopoeia
- AIIMS Formulary
- API Textbook of Medicine
- ICMR Guidelines on Diarrhoeal Management
- National Treatment Guidelines for Acute Diarrhoea (Government of India)
- WHO Model List of Essential Medicines (supportive reference)
- NLEM 2022 (drug status verified — not listed)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...